

MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

1. INTRODUCTION

The Board of Directors (the "**Board**") of Medtecs International Corporation Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 3 December 2024, 27 December 2024 and 17 January 2025 (the "**Announcements**") in relation to, among others, the Winding Up Application and the Court Order in respect of Resilient Medical Pte. Ltd. ("**Resilient Medical**").

Unless otherwise defined herein, capitalised terms used in this announcement shall have the meanings ascribed to them in the Announcements.

2. MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

Pursuant to Rule 704(22) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "**Catalist Rules**"), the Board wishes to update shareholders that:

- (a) the Court had on 21 January 2025 issued its written order that: (i) a winding up order be made against Resilient Medical, (ii) Mr. Wong Pheng Cheong Martin of FTI Consulting (Singapore) Pte. Ltd. be appointed as the sole liquidator of Resilient Medical (the "Liquidator") and (iii) the costs of the proceedings be assessed and to be paid to the Company out of the assets of Resilient Medical;
- (b) the Company intends to file a proof of debt with the Liquidator; and
- (c) there have been no negotiations between the Company and the Company's principal bankers or trustee, as the Liquidator is still in the process of gathering documents. Furthermore, there have been no material developments that could have a significant impact on the Company's financial position.

3. FINANCIAL IMPACT

As at the date of this announcement, the Company is still assessing the impact of the Court Order on the net tangible assets per share of the Company and the earnings per share of the Company for the current financial year ending 31 December 2024 as such impact would be affected by the valuation and methodology of the distribution of assets to be determined by the Liquidator. In the event that there is a material impact on the Group's financials or any further material development on this matter, the Company will make a separate announcement in due course.

The Company will also release further announcements to update its shareholders as and when there are material developments in relation to the winding up of Resilient Medical in between the monthly updates.

4. CAUTION IN TRADING

Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully. Shareholders and potential investors of the Company are advised to refrain from taking any action with respect to their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

Submitted by Mr Clement Yang, Executive Chairman, on 24 January 2025 to the SGX-ST.

This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd. ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**Exchange**").

This document has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this document including the correctness of any of the statements or opinions made or reports contained in this document.

The contact persons for the Sponsor are Ms Evelyn Wee (Telephone Number: +65 6232 0724) and Mr. Howard Cheam Heng Haw (Telephone Number: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View, Marina One West Tower, #06-07 Singapore 018937.